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The combination of fluoxetine 
and environmental enrichment 
reduces postpartum 
stress‑related behaviors 
through the oxytocinergic system 
and HPA axis in mice
Hamideh Bashiri1,2, Danielle J. Houwing3, Judith R. Homberg3 & Ali‑Akbar Salari4*
Gestational stress can increase postpartum depression in women. To treat maternal depression, 
fluoxetine (FLX) is most commonly prescribed. While FLX may be effective for the mother, at high 
doses it may have adverse effects on the fetus. As environmental enrichment (EE) can reduce maternal 
stress effects, we hypothesized that a subthreshold dose of FLX increases the impact of EE to reduce 
anxiety and depression‑like behavior in postpartum dams exposed to gestational stress. We evaluated 
this hypothesis in mice and to assess underlying mechanisms we additionally measured hypothalamic–
pituitary–adrenal (HPA) axis function and brain levels of the hormone oxytocin, which are thought 
to be implicated in postpartum depression. Gestational stress increased anxiety‑ and depression‑
like behavior in postpartum dams. This was accompanied by an increase in HPA axis function and 
a decrease in whole‑brain oxytocin levels in dams. A combination of FLX and EE remediated the 
behavioral, HPA axis and oxytocin changes induced by gestational stress. Central administration of 
an oxytocin receptor antagonist prevented the remediating effect of FLX + EE, indicating that brain 
oxytocin contributes to the effect of FLX + EE. These findings suggest that oxytocin is causally involved 
in FLX + EE mediated remediation of postpartum stress‑related behaviors, and HPA axis function in 
postpartum dams.
Maternal depression frequently occurs during pregnancy, with 1 in 5 women reporting depressive  symptoms1. 
An estimated 3–7% of pregnant women suffer from a major depressive  disorder2–6. Stress-related disorders such 
as depression during late pregnancy are a major risk factor for the development of postpartum  depression7. 
Maternal depression during pregnancy and postpartum period has been associated with adverse effects on child 
 neurodevelopment8–13.
During pregnancy and the postpartum period, the function of the mothers’ hypothalamic pituitary adrenal 
(HPA) axis alters. In postpartum depression hypersecretion of cortisol has been  observed14,15. Besides steroid 
hormones, the peptide hormone oxytocin (OXT) has recently gained attention for potential involvement in 
 depression16–19. For instance, oxytocin was shown to be associated with the HPA axis function and depression 
in postpartum women, suggesting an interaction between oxytocin and glucocorticoids during the postpartum 
period on depressive  behavior20,21.
To treat maternal depression, antidepressant selective serotonin reuptake inhibitors (SSRIs) are most com-
monly prescribed, with an international prevalence estimate of 3.0%22. Like maternal depression, using SSRIs dur-
ing pregnancy can affect neurobehavioral development in the  offspring23–32. In line with the human studies, rodent 
studies found that SSRI exposure during pregnancy and/or the postnatal period resulted in neurodevelopmental 
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alterations in the  offspring33–50. When the SSRI fluoxetine (FLX) is administered to  dams47,51–54 its actions can 
markedly differ when using maternally stressed dams. Besides exerting beneficial effects, there might be risk that 
FLX treatment causes developmental changes in offspring, such as reduced activity and exploration behavior, an 
increased passive stress coping style, and less efficient sensory  processing55. This asks for a more refined treat-
ment regime effective for the mother and safe for the fetus. Environmental enrichment (EE) during pregnancy 
and postpartum period could also remediate anxiety and depression-like behaviors in  mothers56. EE exposure 
affects HPA axis function by reducing stress hormones, including basal adrenocorticotropic hormone (ACTH) 
and corticosterone levels of singly housed male and female  rats57. Furthermore, EE was shown to activate the 
oxytocinergic system in the brain of  mice58. However, it is not known whether EE during pregnancy and post-
partum period can prevent gestational stress-induced depression-like behavior in the postpartum dam.
Of interest, it has recently been proposed that serotonin increases neuroplasticity, and thereby sensitivity to 
environmental stimuli, negative stimuli as well as positive ones such as EE. In support of this  hypothesis59 it has 
been demonstrated that SSRI treatment in combination with an enriched environment reduces depression-like 
behavior in  mice60,61. As to whether these effects extend to maternal depression is up to date unknown. Since 
perinatal FLX exposure can reduce maternal stress effects, we questioned whether a subthreshold dose of FLX 
would increase the impact of EE to reduce maternal depression.
The aim of this study was to investigate the effects of gestational-postpartum treatment with a relatively low 
(5 mg/kg) dose of FLX and EE, both separately as well as combined, on gestational stress-induced postpartum 
anxiety and depression-like behavior in mouse dams. It was our first hypothesis that a low dose of FLX combined 
with EE remediates anxiety- and depression-like behavior in gestationally stressed dams. To investigate underly-
ing mechanisms, we measured HPA axis function, and brain OXT levels. Because we found that gestational stress 
was associated with a decrease in whole-brain oxytocin levels, and a combination of FLX and EE remediated 
anxiety- and depression-like behavior as well as this hormonal change, it was our second hypothesis that OXT 
would be causally involved in the remediation effects of FLX plus EE. To test this hypothesis, we tested whether 
central infusion of an OXT antagonist would prevent the remediation of postpartum stress-related behavior in 
dams following FLX and EE.
Results
Experiment 1. To test our hypotheses we studied the effects of gestational stress, fluoxetine treatment and 
environmental enrichment on anxiety (open field test), depression-like behavior (social interaction and sucrose 
preference, forced swim test), HPA axis function, and OXT in the brain.
Open field test. In the open field test the time spent in the inner zone was used as index of anxiety, which 
was significantly different between groups  (F(4,45) = 5.71, p = 0.002). Posthoc analysis revealed that gestational 
stress reduced the time spent in the inner zone of the open field compared to the non-stress condition, indicat-
ing that the gestational stress increased anxiety (p = 0.002; Fig. 1A). As expected, FLX treatment and EE inde-
pendently could not restore stress-induced anxiety. Interestingly, a combination of FLX treatment and EE in 
stressed dams significantly increased the time spent in the inner zone compared to stressed only dams (p = 0.037; 
Fig. 1A), thus restoring anxiety levels back to normal.
Social interaction test. For the total interaction time we found a significant difference between groups 
 (F(4,45) = 4.79, p = 0.004). Posthoc analysis demonstrated that gestational stress significantly decreased the total 
interaction time relative to the non-stress condition, leading to increased social withdrawal (p = 0.027; Fig. 1B). 
As expected, FLX treatment and EE independently did not restore stress-induced social withdrawal when com-
pared to non-stress dams. However, a combination of FLX treatment and EE in stressed dams increased social 
interaction compared to stressed only dams (p = 0.002; Fig. 1B), indicating that social interaction was restored 
to non-stress level.
Sucrose preference. We further observed that sucrose preference was significantly differed among groups 
 (F(4,45) = 10.14, p < 0.001). A subsequent analysis showed a significant reduction in sucrose preference in gesta-
tional stressed dams, when compared to non-stressed dams (p < 0.001; Fig. 1C). FLX treatment and EE inde-
pendently did not restore stress-induced reductions in sucrose preference. However, FLX treatment and EE 
combined increased sucrose preference in stressed dams compared to stressed dams (p = 0.005; Fig. 1C) and 
stress + FLX dams (p = 0.038; Fig. 1C). This shows that the combination of FLX and EE reduced depression-like 
behavior.
Forced swim test. To measure behavioral despair immobility time was measured, which was significantly 
different between groups  (F(4,45) = 8.27, p < 0.001). Posthoc analysis revealed that gestational stressed dams spent 
more time on immobility compared to non-stressed dams (p = 0.003; Fig. 1D), indicative for increased behav-
ioral despair in stress dams. FLX treatment and EE independently did not reduce time spent on immobility. 
However, a combination of FLX treatment and EE in stressed dams reduced immobility time compared to stress 
dams (p < 0.001), stress + FLX dams (p = 0.026) and stress + EE dams (p = 0.003) (Fig. 1D). This finding suggests 
that combining FLX treatment and EE prevented stress-induced depression-like behavior.
HPA axis function. Both ACTH  (F(4,45) = 4.15, p = 0.006) and corticosterone  (F(4,45) = 4.46, p = 0.005) lev-
els were between groups. As expected, a significant increase in ACTH (p = 0.015; Fig. 2A) and corticosterone 
(p = 0.033; Fig. 2B) levels was found in gestational stressed versus non-stressed postpartum dams. Moreover, the 
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combination of FLX treatment and EE in stressed dams reduced ACTH (p = 0.046; Fig. 2A) and corticosterone 
(p = 0.007; Fig. 2B) levels compared to stress dams. FLX and EE did not independently reduce stress-induced 
ACTH and corticosterone levels. These findings demonstrate that a combination of FLX treatment and EE dur-
ing pregnancy and lactation reduces HPA axis function to gestational stress during the postpartum period.
Brain oxytocin. Lastly, brain OXT levels were significantly different between groups  (F(4,45) = 8.38, p < 0.001). 
Gestational stress significantly reduced OXT levels compared to dams left undisturbed (p < 0.001; Fig. 2C). The 
combination of FLX treatment and EE significantly increased OXT levels compared to both stressed dams 
(p = 0.004) and stress + FLX dams (p = 0.018; Fig. 2C). FLX treatment and EE independently did not increase 
OXT levels (P > 0.05).
Experiment 2. As we observed in experiment 1 the FLX + EE mediated alleviation of the negative effects 
of gestational stress was associated with increased brain OXT levels, we tested in experiment 2 whether OXT 
receptor antagonist treatment could prevent the alleviating effects of FLX + EE. As readouts we focusing on anxi-
ety (open field test) and depression-like behavior (social interaction, sucrose preference, forced swim test) and 
HPA axis function.
Figure 1.  The effects of gestational stress, fluoxetine (FLX) treatment and environmental enrichment on 
anxiety-like behavior in the open field test (A; inner zone time) and depression-like behavior in the social 
interaction (B; total interaction time), sucrose preference (C), and forced swim test (D; immobility time) during 
the postpartum period in dams. Values are presented as mean ± SEM (N = 10). Significant differences: *P < 0.05, 
**P < 0.01 and ***P < 0.001, compared to non-stress group; + P < 0.05, +  + P < 0.01 and +  +  + P < 0.001, compared 
to stress group; #P < 0.05, compared to stress + FLX group; $$P < 0.01, compared to stress + EE group.
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Open field test. One-way ANOVA revealed a significant difference between groups in time spent in the 
inner zone  (F(5,54) = 6.86, p < 0.001). As expected, posthoc analysis showed that gestational stress in dams signifi-
cantly reduced the time spent in the inner zone, indicative for increased anxiety (p = 0.01; Fig. 3A). Furthermore, 
the combination of FLX treatment and EE significantly increased inner zone time compared to stressed only 
dams (p = 0.035; Fig.  3A). These findings confirm our results from experiment 1. No effects of OXT-A were 
observed in any of the groups when compared to vehicle-treated counterparts.
Social interaction test
Regarding total time spent on social interaction we observed a significant difference between groups  (F(5,54) = 9.51, 
p < 0.001). Posthoc analysis revealed a significant reduction in total interaction time in gestational stressed com-
pared to non-stressed dams (p = 0.002; Fig. 3B). In line with our findings from experiment 1, combined FLX 
treatment and EE significantly increased stress-induced total interaction time (p = 0.022; Fig. 3B). When OXT-A 
was administered to stressed dams that received combined FLX treatment and EE, the total interaction time 
significantly decreased compared to vehicle treated counterparts (p = 0.012; Fig. 3B). No effects of OXT-A were 
observed in non-stress and stress dams when compared to vehicle-treated counterparts. These results indicate 
that OXT-A mediated the effects of combined FLX treatment and EE on stress-induced social withdrawal.
Sucrose preference. Sucrose preference was also significantly different between groups  (F(5,54) = 7.53, 
p < 0.001). As expected, gestational stress reduced sucrose preference compared to non-stress dams (p = 0.004; 
Fig. 3C). In addition, the combination of FLX treatment and EE significantly increased sucrose preference in 
stressed compared to non-stressed dams (p = 0.042; Fig. 3C), confirming our results from experiment 1. Inter-
Figure 2.  The effects of gestational stress, fluoxetine (FLX) treatment and environmental enrichment (EE) on 
ACTH (A) and corticosterone (B) in the serum, and oxytocin levels in the brain (C) during the postpartum 
period in dams. Values are presented as mean ± SEM (N = 10). Significant differences: *P < 0.05 and ***P < 0.001, 
compared to non-stress group; + P < 0.05 and +  + P < 0.01, compared to stress group; #P < 0.05, compared to 
stress + FLX group.
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estingly, OXT-A prevented the increase in sucrose preference that was observed after combined FLX treatment 
and EE in stress dams (p = 0.007; Fig. 3C), while no effects of OXT-A were observed in non-stress and stress 
dams when compared to vehicle-treated counterparts. These results indicate that OXT-A mediated the effects of 
combined FLX treatment and EE on stress-induced alterations in anhedonia-like behavior.
Forced swim test. The significant group differences in time spent on immobility  (F(5,54) = 8.58, p < 0.001), a 
measure of behavioral despair, were followed-up by posthoc analyses showed that gestational stress significantly 
increased immobility time relative to the non-stress condition (p = 0.012; Fig.  3D). The combination of FLX 
Figure 3.  The effects of treatment with oxytocin receptor antagonist (OXT-A) following gestational stress, 
and fluoxetine treatment plus environmental enrichment (FLX + EE) on anxiety-like behavior in the open 
field test (A; inner zone time) and depression-like behavior in the social interaction (B; total interaction time), 
sucrose preference (C), and forced swim test (D; immobility time) during the postpartum period in dams. 
Values are presented as mean ± SEM (N = 10). Significant differences: *P < 0.05 and **P < 0.01, compared to 
non-stress group; + P < 0.05 and +  + P < 0.01, compared to stress group; &P < 0.05 and &&P < 0.01, compared to 
stress + FLX + EE + vehicle group.
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treatment and EE reduced the stress-induced increase in immobility time (p = 0.001; Fig. 3D). OXT-A prevented 
the effects of combined FLX treatment and EE on stress-induced immobility time (p = 0.021; Fig. 3D), while no 
effects of OXT-A were observed in non-stress and stress dams when compared to vehicle-treated counterparts. 
These results demonstrate that OXT plays a role in FLX + EE effects on stress-induced behavioral despair.
HPA axis function. Lastly, we analyzed plasma ACTH and corticosterone levels. Group differences in 
ATCH  (F(5,54) = 8.11, p < 0.001) and corticosterone  (F(5,54) = 6.85, p < 0.001) levels were explained by a signifi-
cant increase in both ACTH (p = 0.004; Fig. 4A) and corticosterone (p = 0.042; Fig. 4B) levels after gestational 
stress. Furthermore, the combination of FLX treatment and EE significantly reduced ACTH (p = 0.047; Fig. 4A) 
and corticosterone (p = 0.014; Fig. 4B) levels, showing preventive effects of FLX + EE on stress-induced changes 
in HPA-axis activity. OXT-A administration in stressed dams exposed to FLX treatment and EE significantly 
increased corticosterone –but not ACTH- levels compared to vehicle treated counterparts (p = 0.001; Fig. 4B). 
No effects of OXT-A were observed in non-stress and stress dams compared to vehicle treated dams. These find-
ings demonstrate that OXT mediated the FLX + EE effects on stress-induced HPA-axis function.
Discussion
In line with our hypothesis, we found that stress applied during pregnancy increased anxiety- and depression-like 
behavior in postpartum dams. This was accompanied by an increase in HPA axis function and an unexpected 
decrease in OXT levels in the dam. Further, as we hypothesized, a combination of subthreshold FLX and non-
significant EE remediated the behavioral, HPA axis and OXT changes induced by gestational stress in postpartum 
dams. Central administration of an OXT receptor antagonist prevented the remediating effect of subthreshold 
FLX + non-significant EE, showing that brain OXT contributes to the combined effect of FLX and EE. The finding 
that gestational stress induced anxiety- and depression-like behavior in postpartum dams is in line with previous 
findings and suggests that stress during pregnancy can still exert its effects during the early postnatal period, 
when stress is  absent51,62. This comes as no surprise, as maternal anxiety and depression during pregnancy is 
strongly associated with postpartum depressive symptoms in  humans63.
Previous work from our group shows that perinatal FLX treatment with a higher dose (8 mg/kg) prevents 
depression-like behavior in postpartum  dams51, while others show that effects of pre-gestational stress on serum 
corticosterone levels in postpartum dams can be reversed by perinatal treatment with 10 mg/kg  FLX64. To date, 
studies directly investigating the effects of EE during pregnancy on gestationally stressed dams are lacking. Spar-
ling et al. showed that the behavior of dams can be beneficially affected by a combination of physical and social 
enrichment during the gestational and postpartum  periods65. However, rat dams housed in an enriched condition 
during their pregnancy and the postpartum period did not display any differences in anxiety-and depression-
related symptoms compared to the control  dams65–67. Most of the beneficial effects are exerted by EE consisting of 
increased cage complexity (larger cage, adding objects/shelters and a running wheel) and/or social enrichment. 
In the present study, we only increased cage complexity, which was by itself not strong enough to alter maternal 
anxiety- and depression-like behavior. We show, in line with the hypothesis that serotonin increase susceptibil-
ity to environmental stimuli such as  EE59, that altering serotonin levels through subthreshold FLX treatment 
may enhance neuronal plasticity, rendering it more susceptible to the beneficial effects of non-significant EE.
Figure 4.  The effects of treatment with oxytocin receptor antagonist (OXT-A) following gestational stress, 
and fluoxetine treatment plus environmental enrichment (FLX + EE) on ACTH (A) and corticosterone (B) in 
the serum during the postpartum period in dams. Values are presented as mean ± SEM (N = 10). Significant 
differences: *P < 0.05 and **P < 0.01, compared to non-stress group; + P < 0.05, compared to stress group; 
&&P < 0.01, compared to stress + FLX + EE + vehicle group.
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Changes in HPA axis function are important mediators of the effects of gestational stress on postpartum 
anxiety- and depression-like behavior. We have previously shown that gestational stress can increase basal and 
stress-induced corticosterone levels in postpartum  dams51. However, others have found that when the stress is 
pre-gestational, basal corticosterone levels were reduced postpartum and restored by perinatal FLX  treatment64. 
These findings show that the timing of the stress and FLX treatment of the dams may differentially impact mater-
nal corticosterone levels. We further observed that high corticosterone levels were correlated with increased 
forced swim test immobility and less social interaction. These results are in line with human findings, where a 
correlation between postpartum depression and abnormal HPA axis function and hypersecretion of cortisol is 
well-established14,15. Although studies have shown that EE can reduce HPA axis function by decreasing basal 
ACTH and corticosterone levels in  rodents68,69, there are no reports studying the effect of EE on HPA axis activity 
in pregnant and postpartum dams. What makes our findings important is that we show that a combination of 
FLX and EE could reduce HPA axis function in dams. Further studies are needed to focus on different protocols 
of EE on HPA axis function during pregnancy and the postpartum period.
We further found that the gestational stress-induced anxiety and depression-like symptoms were paral-
leled by a decreased in whole-brain OXT levels. Interestingly, FLX + EE was related to decreased anxiety and 
depression-like behaviors and increased brain OXT levels. Brain OXT is one of the most important regulators 
of anxiety and depression in both humans and  rodents70. OXT exerts anxiolytic and antidepressant effects and 
modulates neuronal functions associated with stress  responses70. For example, intranasal OXT treatment was 
shown to decrease HPA axis activity, anxiety- and depression-related  symptoms71–73. Since there is a significant 
comorbidity between these  disorders74,75, common mediators such as OXT are presumably to underlie both 
psychiatric  disorders70. In line with these studies, recent clinical and experimental researches have revealed that 
OXT treatment could be an interesting therapeutic strategy for postpartum  depression16.
To investigate whether brain OXT is causally related to the remediating effects of FLX + EE we tested the 
effects of OXT-A treatment on anxiety- and depression-like behavior as well as HPA-axis function. Treatment 
with OXT-A did not further increase ACTH and corticosterone or behavioral measures in dams that were stressed 
during pregnancy, but did prevent the remediation of stress-induced effects by perinatal FLX treatment and 
EE. These findings indicate that OXT is causally involved in FLX + EE mediated remediation of stress-induced 
effects on HPA-axis function and anxiety- and depression-like behavior. In support of our findings, it has been 
recognized that EE exposure enhanced oxytocinergic system in the  brain58,76. Besides, no significant changes 
were found following chronic treatment with SSRIs such as fluoxetine in basal oxytocin  levels77. Interestingly, 
Cox et al., reported that the OXT surge during breastfeeding in women with or without anxiety and depression 
symptoms buffers stress-induced corticosterone secretion. They also found that postpartum depressed women 
had lower OXT levels during feeding than women without  depression21. The present study shows that a significant 
increase of brain OXT levels following FLX + EE exposure could conceivably decrease anxiety and depression-
related behaviors by reducing HPA axis function in stressed postpartum dams.
A unique aspect of this study that the behavior and hormonal state of dams was studied after exposure to 
various combinations of stress, FLX treatment and EE exposure. A notable limitation of is that we did not meas-
ure maternal behavior. Although the litters were culled to 8 mice (4 males, 4 females), we cannot exclude the 
possibility that changes in mother–pup interactions affected mother behavior and accordingly influenced the 
behavioral measurements in the dams. Taken together, our findings confirm and extend earlier research demon-
strating OXT as an important player in the regulation of anxiety and depression during the postpartum period.
Methods
Animals. A total of 110 timed-pregnant NMRI mice (12–13 weeks old; 22–25 g) were produced in the animal 
facility at “Salari Institute of Cognitive and Behavioral Disorders (SICBD)”. All the experiments were performed 
in SICBD. The breeding procedure was performed as previously  described78. To expose the female mice to male 
pheromones, two male and four female mice were placed in a partitioned cage with no physical contact for 
3 days. In the next step, male and female mice were put in a cage one-by-one. The next morning (7:00 A.M.), the 
presence of a vaginal plug was considered a successful mating and gestational day (GD 0). Pregnant mice were 
housed individually in enriched or standard polycarbonate cages under standard laboratory conditions (12:12 h 
light/dark cycle; lights on 7:00 a.m.; temperature 23 ± 1 °C; humidity 40–50%). Food and water were available 
ad  libitum. The experiments were approved by the Research and Ethics Committee of Kerman University of 
Medical Sciences (IR.KMU.REC.1399.325) and were in compliance with ARRIVE guidelines. All methods were 
also performed in accordance with the relevant guidelines and regulations.
Experimental design. A schematic timeline of the experimental design is shown in Fig. 5. Experiment 
1 investigated the combined effects of subthreshold FLX and non-significant EE (see explanation below) on 
postpartum anxiety and depression-like behavior, HPA  axis function, and whole-brain OXT levels in gesta-
tional stressed dams. Pregnant mice were randomly divided into five groups (non-stress, stress, stress + FLX, 
stress + EE, and stress + FLX + EE). The mice were subjected to stress (stress) or left undisturbed (non-stress) 
during pregnancy (GD5 to GD19). In addition to stress, mice received FLX treatment (stress + FLX) in their 
drinking water (GD10 to PPD10), were housed in enriched cages (stress + EE; GD0 to PPD10) or were subjected 
to both FLX treatment and EE (stress + FLX + EE) during pregnancy. The FLX treatment period was selected 
based on the birth of serotonin neurons occurring at embryonic day 10.5 in  mice79 and the correspondence of 
PPD10 in rodents to birth in  humans80.
Experiment 2 investigated the role of OXT in the combined effects of subthreshold FLX and non-significant 
EE on gestational stress-induced changes in anxiety and depression-like behaviors, and HPA axis function, 
during the postpartum period in dams. To do so, OXT signaling was inhibited by blocking OXT receptors via 
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brain infusion with an OXT receptor antagonist during the postpartum period. First, female mice underwent 
stereotaxic surgery 10–12 days before pregnancy (GD0). Then, pregnant mice were randomly divided into six 
groups (non-stress + vehicle, non-stress + OXT-A, stress + vehicle, stress + OXT-A, stress + FLX + EE + vehicle, 
and stress + FLX + EE + OXT-A). Pregnant mice were subjected to stress (GD5 to GD19) (stress), stress with 
a combination of FLX treatment (GD10 to PPD10) and EE (GD0 to PPD10) (stress + FLX + EE), or were left 
undisturbed (non-stress). During the postpartum period (PPD1 to PPD10) all groups received either an OXT 
antagonist (OXT-A) or vehicle (artificial cerebrospinal fluid; aCSF).
In both experiments, the dams were subjected to the open field-, social interaction-, sucrose preference-, and 
forced swim-test during the postpartum period. In experiment 1 and 2, serum adrenocorticotropic hormone 
(ACTH) and corticosterone were measured. In experiment 1, OXT levels in the brain were measured as well. In 
both experiment 1 and 2, ten animals were included in each group (n = 10/group).
Environmental enrichment. Female mice were housed individually in enriched or standard environ-
ments during pregnancy and the postpartum period (GD0 to PPD 10)81. The enriched environment consisted 
of polycarbonate cages (58 × 38 × 20 cm) equipped with two plastic shelters, four tunnels and two cotton nest-
lets that were replaced once a week during cage cleaning with new objects of different shapes and colors. This 
enriched environment was selected based on our pilot studies that found no significant effects of EE on dams’ 
behaviors. The standard environment consisted of standard polycarbonate cages (27 × 21 × 14 cm) with only one 
cotton nestlet.
Gestational restraint stress. Between GD 5 and 19, pregnant mice were exposed to three daily stress ses-
sions. Briefly, dams were individually placed in plastic transparent cylinders (4 cm diameter, 10 cm long) under 
a single 60-W light bulb for 30 min as previously  described51. There was a 3 h interval time between each session, 
Figure 5.  Experiment 1 tested the effects of gestational stress, fluoxetine treatment and environmental 
enrichment on anxiety (open field test), depression-like behavior (social interaction and sucrose preference, 
forced swim test), HPA-axis function (serum ACTH and corticosterone), and oxytocin in the brain during the 
postpartum period in dams. Experiment 2 investigated the FLX + EE mediated alleviation of the negative effects 
of gestational stress through blocking oxytocin receptor on anxiety and depression-like behavior, and HPA-axis 
function during the postpartum period in dams.
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the animals were exposed to the restraint stress between 10:00 (A.M.) and 7:00 (P.M.). Non-stressed dams were 
left undisturbed during pregnancy in their cages. We have previously shown that stress during these gestational 
days in female NMRI mice increases depression-related behaviors during the postpartum  period51. To avoid 
litter effects on maternal anxiety and depression-like behaviors, all litters were culled to 8 pups (4 males and 4 
females) per  mother82.
Maternal fluoxetine treatment. Five days after starting the restraint stress procedure, the pregnant 
mice were treated with FLX hydrochloride (TEMAD Co., Tehran, Iran; 5 mg/kg/day) during pregnancy and the 
postpartum period (GD10 to PPD 10) as previously  described51. To minimize the unknown effects of repeated 
administration stress following drug treatment by invasive and stressful procedures resulting from repeated 
injections, osmotic minipumps or oral gavages, dams received FLX or vehicle (water) via regular drinking bot-
tles. The FLX concentration was calculated at five-day intervals based on the average liquid consumption and 
body weight of the  dams51. There was no other source for water except the drinking water containing FLX, 
therefore, dams were motivated by the thirst to drink the FLX solutions. The liquid consumptions of the vehicle-
treated mice were evaluated every five days to assess possible impacts of the chronic FLX treatment on the liquid 
intake. No significant alterations were found between vehicle and FLX treated dams. The FLX dose was chosen 
based on our recent studies (Amani et al., under review) in which FLX did not influence HPA axis function, 
anxiety and depression-like behavior in postpartum dams.
Stereotaxic surgery and OXT receptor blockade. In experiment 2, adult female mice underwent ste-
reotactic surgery to enable brain infusions with OXT-A. Female mice were anesthetized by a combination of ket-
amine and xylazine (50 and 4 mg/kg respectively, Alfasan Co, Netherlands) and placed in a Stoelting stereotaxic 
instrument. Two single stainless-steel guide cannulae (26-gauge) were implanted into the left and right lateral 
ventricle (anteroposterior (AP): − 0.34 mm; mediolateral (ML): ± 1.0 mm; dorsal ventricular (DV): 2 mm;83. The 
guide cannulae were anchored to four micro stainless-steel screws using dental acrylic cement. A stainless-steel 
stylet (33-gauge) was inserted into each guide cannula to keep it free of debris and clogging. Female mice were 
allowed to recover from surgery for six days before breeding commenced. The left and right lateral ventricle were 
infused with OXT-A or vehicle (1 µl/mouse, 0.5 µl/side) by means of an internal cannula (33-gauge), terminating 
1 mm below the tip of the guide, connected by polyethylene tubing to a 1-μl Hamilton syringe. The inner cannula 
was left in place for an additional 60 s to allow diffusion of the solution and to reduce the possibility of  reflux84. 
OXT antagonist (OXT-A; (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, Bachem, Co) was dissolved 
in highly purified acetic acid artificial cerebrospinal fluid (aCSF) as described  previously85. Postpartum dams 
received a daily intracerebroventricular infusion with a subthreshold dose of OXT-A (0.5 µg/1 µl/mouse) or 
vehicle (1 µl/mouse; aCSF) for 10 days (PPD1 to PPD 10). Behavioral testing or sampling in the dam occurred 
two hours after the injection. The location of infusion was checked post-mortem and no damage to other tissues 
than the track towards the targeted regions was found.
Behavioral tests. To control for bias, behavioral measurements were carried out and observed by an expert 
observer blind to the treatment condition. All behavioral measurements were recorded using a stopwatch and 
performed during the light period (between 12:00 and 16:00 h) under illumination of 75 lx.
Open field test. To assess anxiety-like behavior, the dams were subjected to the open field test on PPD 2 as 
previously  described86. The apparatus consisted of a white box (40 × 40 × 20 cm) with one outer (10 × 10 cm; 12 
squares) and inner (10 × 10 cm; 4 squares) zone. Each dam was placed in the middle of the apparatus and allowed 
to explore for 5 min. The time spent (s) in the inner zone was used as an index of anxiety-like behavior.
Social interaction test. Social interaction was assessed on PPD 5 in dams as previously  described87. 
Briefly, each dam was exposed to an unfamiliar same-treated dam (that was used in a parallel study). Animals 
were gently placed in opposite corners of a square (40 × 40 × 20 cm) arena and allowed to explore the apparatus 
for 7 min. The interaction between animals was defined as sniffing (the focal animal establishes contact or near-
contact with its nose to the other animals’ body part), following (the focal animal moves/follow the other to 
maintain a close distance while the other animal is moving around/away), grooming (the focal grooming animal 
has one or both front paws on top of the other and pulls/licks at its fur), and climbing over each other (the focal 
animal climbs over the dorsal surface of the other animal)88. The total time interaction was measured as an index 
of social behavior.
Sucrose preference. The sucrose preference test was performed over on PPD 7 as described previously by our 
 group51. The percentage of sucrose preference was considered as an anhedonia-like symptom. In short, after 
three days of acclimation to the two-bottle choice paradigm, each animal was given two bottles over a 48-h 
period: one containing a 2% sucrose solution or 2% sucrose solution + FLX (A) and the other containing tap 
water or water + FLX (B). The position of the bottles A and B was changed every 12 h to avoid side bias. The 
sucrose preference was calculated as the percentage of sucrose solution ingested relative to the total amount of 
liquid consumed.
Forced swim test. To assess behavioral despair, dams were subjected to the forced swim test on PPD 9. Immo-
bility time was considered as a state of behavioral  despair82. In short, dams were placed individually in transpar-
ent glass cylinders (height: 25 cm, diameter: 10 cm, depth: 15 cm) filled with fresh water (25 ± 1 °C) and the total 
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duration of immobility was recorded for 6 min, of which the last 4 were analyzed. Each dam was considered 
immobile when it ceased struggling and remained floating motionless in the water, making only those move-
ments necessary to keep its head above water.
Enzyme‑linked immunosorbent assay (ELISA). On PPD 10, the dams were anesthetized with pentobarbital 
(60  mg/kg, ip; between 12:00 and 16:00  h), blood and brain tissue were collected as previously  described51. 
Briefly, trunk blood was collected into sterile 2 ml microtubes, allowed to clot on ice-packs (15 min), and cen-
trifuged at 3000 rpm for 10 min to detect serum. After collecting the blood, mice were perfused with ice-cold 
NaCl, 0.9% to prevent the retention of blood in the brain. Afterwards, whole brain was rapidly removed, snap 
frozen in liquid nitrogen, and placed into 2 ml microtubes. All serum and brain samples were stored at − 80 °C 
until further processing. ACTH (Abcam Co, ab263880; sensitivity = 6 pg/ml) and corticosterone (Mybiosource, 
MBS264846; sensitivity = 1  ng/ml) were measured in serum, and OXT (Mybiosource, MBS745701; sensitiv-
ity = 1 pg/ml) was measured in brain tissue using specific quantitative sandwich ELISA kits according to the 
manufacturer’s instructions. All samples and standards were assayed in duplicate. To obtain brain tissue super-
natant, whole brain tissue was added to 1000 μl homogenizing buffer including TBS plus 0.2% Triton X-100, 
2 mM EDTA, PBS 1 mM PMSF, and protease inhibitors, and then centrifuged at 15,000 g for 15 min at 4 °C82. 
The total protein levels were also determined by the bicinchoninic acid assay kit (Sigma Co, BCA1). The con-
centration of OXT is presented as pg/mg protein. Whole-brain analysis was performed since neuropathologies 
underlying brain disorders are dispersed over the brain, as evidenced by the involvement of various large-scale 
brain networks in depression in  humans89 and susceptibility to depression-like behavior in  rodents82,90,91.
Data analysis. One-way analysis of variance (ANOVA; IBM-SPSS software-26) was used to analyze the data 
(no data were excluded). For each behavior test p-value was corrected for multiple testing (adjusted p value) 
using the Benjamini–Hochberg  method92. Further analysis was carried out using Tukey’s HSD post hoc tests for 
multiple comparisons. All data are presented as the mean + standard error of the mean (SEM). A p-value < 0.05 
was considered statistically significant.
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